Please login to the form below
SEC
This page shows the latest SEC news and features for those working in and with pharma, biotech and healthcare.
Lilly ends $1.4bn deal with immuno-oncology biotech NextCure
NextCure did not reveal why Lilly decided to terminate the agreement, saying in a brief US Securities and Exchange Commission (SEC) filing:. ... Shares in the biotech fell shortly after the SEC filing was released – the company is also due to present
Latest news
-
MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
In an SEC filing, it said the cuts are focused on 'further optimising the company’s manufacturing and supply network, as well as reducing its global real estate footprint'.
-
France’s Innate Pharma eyes $100m Nasdaq IPO
filed with the US Securities &Exchange Commission (SEC).
-
‘Missing protein’ biotech Stoke raises $142m in IPO
In Stoke’s IPO prospectus filed with the Securities &Exchange Commission (SEC), the company says it will file for approval to start trials of STK-001 early in 2020 and will
-
‘Missing protein’ biotech Stoke raises $142m in IPO
In Stoke’s IPO prospectus filed with the Securities &Exchange Commission (SEC), the company says it will file for approval to start trials of STK-001 early in 2020 and will
-
AZ preps new roxadustat filings, though data foxes investors
FibroGen’s sell-off seemed to relate to what some observers considered was cautious language in the company’s recent 10-Q filing with the Securities &Exchange Commission (SEC) on the
More from news
Approximately 2 fully matching, plus 63 partially matching documents found.
Latest Intelligence
-
Creating a successful global compliance programme
The importance of effective compliance programmes was highlighted in the DOJ and SEC’s Resource Guide to the US Foreign Corrupt Practices Act, which describes in detail the hallmarks of a
-
Deal Watch January 2018
However, in the meantime the US Securities and Exchange Commission (SEC) has issued a lawsuit against some traders for insider trading based on a series of suspicious transactions that made about
-
US health reforms
In March, the Securities and Exchange Commission (SEC) only narrowly blocked this move.
-
Deal Watch - May 2017
A good example is Abbott’s acquisition of the diagnostics company Alere signed in February 2016. Two months later Abbott asked Alere to cancel the transaction because of a SEC inquiry ... into accounting issues at Alere and offered $30m to $50m
-
On the road with the millennial HCP
Yeah I'll put Andy on. Just hang on a sec, he's just sorting our next lift.”.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
RSA announces three new UK hires
In 2009, de Luis moved to the UK with SEC Recruitment and spent three years focussing on the Spanish pharmaceutical market across a number of functional areas.
-
Scottish cabinet reshuffle sees Alex Neil made health secretary
Commenting on Twitter, Sturgeon said: “It has been a privilege to have been Health Sec[retary] - my thanks to all the wonderful people I have worked with.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
SALES ACCELERANT
We help companies to engage prim/sec care healthcare professionals more efficiently and effectively to drive sales growth.
-
SEC Pharma
Analysis, SEC can assist wherever you are looking to hire or work throughout the UK and Europe.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- New study identifies drugs that are safe to use in COVID-19 treatment
- Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients
- Moderna’s COVID-19 vaccine appears effective against UK and South Africa variants
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- UK study finds antibiotics azithromycin and doxycycline ineffective against COVID-19
- Merck ends its COVID-19 vaccine programme after disappointing early trial results
- Wilmington Healthcare appoints new Head of Digital
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- An EU emergency health fund to limit the impact of future crises
- Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
Quick links
Infographics
